First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer

Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters

A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells

Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets

Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo

Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism

Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways

Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models

ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms

Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts

Muralidharan Anbalagan, Alaa Ali, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan
1948 | Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

1959 | TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Lievehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg

1968 | Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguirar, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angelina S. Andrew, Vincent Memoli, and Ethan Dmitrovsky

1978 | Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

1988 | YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar

1999 | The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra, and N.V. Rajeshkumar

2001 | Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

2008 | The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is A Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneeet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

2011 | MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
Judy Qujua Shi, Kerri Lasky, Vanshali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe Nestor, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’ Amore, and Marc L. Hyer

2014 | Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

2015 | MOLECULAR MEDICINE IN PRACTICE

2016 | Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alsina, Jaume Capdevila, Jose Perez-Garcia, Gessami Sanchez-Olle, Claudia Aura, Ludmila Prudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero

2017 | Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

2019 | Fibroblast Growth Factor Receptor 2 IIIC as a Therapeutic Target for Colorectal Cancer Cells
Yoko Matsuda, Masahito Hagio, Tomoko Seya, and Toshiyuki Ishiwata

2020 | Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors
ABOUT THE COVER

Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.